Eloralintide
Also called LY3841136
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Eloralintide phase 2 trial
Once weekly; separate 1, 3, 6 and 9 mg groups and two escalation groups
48 weeks
Billings et al., Lancet (2025) ↗When results may show
- When change was measured
- The primary endpoint was percentage weight change at week 48. Fixed-dose and escalation groups must remain separate.
- When to assess
- 48 weeks
- Conditions and limitations
- 263 adults with obesity or overweight plus a related condition, without type 2 diabetes. The abstract does not establish a complete universal starter schedule, maintenance cycle or seller-product equivalence.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Billings et al., Lancet (2025)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Eloralintide describe 1–3 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Billings et al., Lancet (2025)The abstract does not establish a complete universal starter schedule, maintenance cycle or seller-product equivalence.
Next steps
Eloralintide beginner guideOpen Eloralintide planning worksheetEstimate Eloralintide vial costTrack Eloralintide notes